260 related articles for article (PubMed ID: 29747595)
1. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.
Lombardi G; Bellu L; Pambuku A; Della Puppa A; Fiduccia P; Farina M; D'Avella D; Zagonel V
J Neurooncol; 2016 Jul; 128(3):481-6. PubMed ID: 27165580
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of extended-dose temozolomide in patients with melanoma.
Rietschel P; Wolchok JD; Krown S; Gerst S; Jungbluth AA; Busam K; Smith K; Orlow I; Panageas K; Chapman PB
J Clin Oncol; 2008 May; 26(14):2299-304. PubMed ID: 18467721
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
7. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
[TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
[TBL] [Abstract][Full Text] [Related]
11. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Cutaia O; Amato G; Covre A; Camerini R; Calabrò L; Valente M; Giannarelli D; Mandalà M; Maio M
Clin Cancer Res; 2021 Sep; 27(17):4737-4745. PubMed ID: 34112708
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Tas F; Camlica H; Topuz E
Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.
Morano F; Corallo S; Niger M; Barault L; Milione M; Berenato R; Moretto R; Randon G; Antista M; Belfiore A; Raimondi A; Nichetti F; Martinetti A; Battaglia L; Perrone F; Pruneri G; Falcone A; Di Bartolomeo M; de Braud F; Di Nicolantonio F; Cremolini C; Pietrantonio F
Ann Oncol; 2018 Aug; 29(8):1800-1806. PubMed ID: 29860358
[TBL] [Abstract][Full Text] [Related]
17. Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?
Gallo C; Buonerba C; Di Lorenzo G; Romeo V; De Placido S; Marinelli A
J Neurooncol; 2010 Nov; 100(2):311-9. PubMed ID: 20556481
[TBL] [Abstract][Full Text] [Related]
18. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
19. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
20. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]